Global Anti - Neoplastic Agents Market Insights, Forecast to 2025
- 1.4.1 Research Process
- 1.4.2 Data Triangulation
- 1.4.3 Research Approach
- 1.4.4 Base Year
- 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
- 1.5.2 Covid-19 Impact: Commodity Prices Indices
- 1.5.3 Covid-19 Impact: Global Major Government Policy
2 Global Anti - Neoplastic Agents Quarterly Market Size Analysis
- 2.1 Anti - Neoplastic Agents Business Impact Assessment - COVID-19
- 2.1.1 Global Anti - Neoplastic Agents Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.1.2 Global Anti - Neoplastic Agents Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.2 Global Anti - Neoplastic Agents Quarterly Market Size 2020-2021
- 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
- 2.3.1 Drivers
- 2.3.2 Restraints
- 2.3.3 Opportunities
- 2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
- 3.1 Global Anti - Neoplastic Agents Quarterly Market Size by Manufacturers, 2019 VS 2020
- 3.2 Global Anti - Neoplastic Agents Factory Price by Manufacturers
- 3.3 Location of Key Manufacturers Anti - Neoplastic Agents Manufacturing Factories and Area Served
- 3.4 Date of Key Manufacturers Enter into Anti - Neoplastic Agents Market
- 3.5 Key Manufacturers Anti - Neoplastic Agents Product Offered
- 3.6 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Anti - Neoplastic Agents Segments, By Type
- 4.1 Introduction
- 1.4.1 Chemotherapy
- 1.4.2 Targeted Therapy
- 1.4.3 Immunotherapy
- 1.4.4 Hormonal Therapy (Biologic Therapy)
- 1.4.5 Others
- 4.2 By Type, Global Anti - Neoplastic Agents Market Size, 2019-2021
- 4.2.1 By Type, Global Anti - Neoplastic Agents Market Size by Type, 2020-2021
- 4.2.2 By Type, Global Anti - Neoplastic Agents Price, 2020-2021
5 Impact of Covid-19 on Anti - Neoplastic Agents Segments, By Application
- 5.1 Overview
- 5.5.1 Blood Cancer
- 5.5.2 Breast Cancer
- 5.5.3 Gastrointestinal Cancer
- 5.5.4 Prostate Cancer
- 5.5.5 Respiratory/Lung Cancer
- 5.5.6 Other Cancers
- 5.2 By Application, Global Anti - Neoplastic Agents Market Size, 2019-2021
- 5.2.1 By Application, Global Anti - Neoplastic Agents Market Size by Application, 2019-2021
- 5.2.2 By Application, Global Anti - Neoplastic Agents Price, 2020-2021
6 Geographic Analysis
- 6.1 Introduction
- 6.2 North America
- 6.2.1 Macroeconomic Indicators of US
- 6.2.2 US
- 6.2.3 Canada
- 6.3 Europe
- 6.3.1 Macroeconomic Indicators of Europe
- 6.3.2 Germany
- 6.3.3 France
- 6.3.4 UK
- 6.3.5 Italy
- 6.4 Asia-Pacific
- 6.4.1 Macroeconomic Indicators of Asia-Pacific
- 6.4.2 China
- 6.4.3 Japan
- 6.4.4 South Korea
- 6.4.5 India
- 6.4.6 ASEAN
- 6.5 Rest of World
- 6.5.1 Latin America
- 6.5.2 Middle East and Africa
7 Company Profiles
- 7.1 Roche
- 7.1.1 Roche Business Overview
- 7.1.2 Roche Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.1.3 Roche Anti - Neoplastic Agents Product Introduction
- 7.1.4 Roche Response to COVID-19 and Related Developments
- 7.2 Novartis
- 7.2.1 Novartis Business Overview
- 7.2.2 Novartis Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.2.3 Novartis Anti - Neoplastic Agents Product Introduction
- 7.2.4 Novartis Response to COVID-19 and Related Developments
- 7.3 Celgene
- 7.3.1 Celgene Business Overview
- 7.3.2 Celgene Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.3.3 Celgene Anti - Neoplastic Agents Product Introduction
- 7.3.4 Celgene Response to COVID-19 and Related Developments
- 7.4 Bristol-Myers Squibb
- 7.4.1 Bristol-Myers Squibb Business Overview
- 7.4.2 Bristol-Myers Squibb Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.4.3 Bristol-Myers Squibb Anti - Neoplastic Agents Product Introduction
- 7.4.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
- 7.5 Amgen
- 7.5.1 Amgen Business Overview
- 7.5.2 Amgen Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.5.3 Amgen Anti - Neoplastic Agents Product Introduction
- 7.5.4 Amgen Response to COVID-19 and Related Developments
- 7.6 Johnson & Johnson
- 7.6.1 Johnson & Johnson Business Overview
- 7.6.2 Johnson & Johnson Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.6.3 Johnson & Johnson Anti - Neoplastic Agents Product Introduction
- 7.6.4 Johnson & Johnson Response to COVID-19 and Related Developments
- 7.7 Pfizer
- 7.7.1 Pfizer Business Overview
- 7.7.2 Pfizer Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.7.3 Pfizer Anti - Neoplastic Agents Product Introduction
- 7.7.4 Pfizer Response to COVID-19 and Related Developments
- 7.8 Takeda
- 7.8.1 Takeda Business Overview
- 7.8.2 Takeda Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.8.3 Takeda Anti - Neoplastic Agents Product Introduction
- 7.8.4 Takeda Response to COVID-19 and Related Developments
- 7.9 Eli Lilly
- 7.9.1 Eli Lilly Business Overview
- 7.9.2 Eli Lilly Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.9.3 Eli Lilly Anti - Neoplastic Agents Product Introduction
- 7.9.4 Eli Lilly Response to COVID-19 and Related Developments
- 7.10 AstraZeneca
- 7.10.1 AstraZeneca Business Overview
- 7.10.2 AstraZeneca Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.10.3 AstraZeneca Anti - Neoplastic Agents Product Introduction
- 7.10.4 AstraZeneca Response to COVID-19 and Related Developments
- 7.11 Astellas
- 7.11.1 Astellas Business Overview
- 7.11.2 Astellas Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.11.3 Astellas Anti - Neoplastic Agents Product Introduction
- 7.11.4 Astellas Response to COVID-19 and Related Developments
- 7.12 Merck & Co.
- 7.12.1 Merck & Co. Business Overview
- 7.12.2 Merck & Co. Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.12.3 Merck & Co. Anti - Neoplastic Agents Product Introduction
- 7.12.4 Merck & Co. Response to COVID-19 and Related Developments
- 7.13 Sanofi
- 7.13.1 Sanofi Business Overview
- 7.13.2 Sanofi Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.13.3 Sanofi Anti - Neoplastic Agents Product Introduction
- 7.13.4 Sanofi Response to COVID-19 and Related Developments
- 7.14 Bayer
- 7.14.1 Bayer Business Overview
- 7.14.2 Bayer Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.14.3 Bayer Anti - Neoplastic Agents Product Introduction
- 7.14.4 Bayer Response to COVID-19 and Related Developments
- 7.15 Biogen Idec
- 7.15.1 Biogen Idec Business Overview
- 7.15.2 Biogen Idec Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.15.3 Biogen Idec Anti - Neoplastic Agents Product Introduction
- 7.15.4 Biogen Idec Response to COVID-19 and Related Developments
- 7.16 Eisai
- 7.16.1 Eisai Business Overview
- 7.16.2 Eisai Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.16.3 Eisai Anti - Neoplastic Agents Product Introduction
- 7.16.4 Eisai Response to COVID-19 and Related Developments
- 7.17 Teva
- 7.17.1 Teva Business Overview
- 7.17.2 Teva Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.17.3 Teva Anti - Neoplastic Agents Product Introduction
- 7.17.4 Teva Response to COVID-19 and Related Developments
- 7.18 Otsuka
- 7.18.1 Otsuka Business Overview
- 7.18.2 Otsuka Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.18.3 Otsuka Anti - Neoplastic Agents Product Introduction
- 7.18.4 Otsuka Response to COVID-19 and Related Developments
- 7.19 Merck KGaA
- 7.19.1 Merck KGaA Business Overview
- 7.19.2 Merck KGaA Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.19.3 Merck KGaA Anti - Neoplastic Agents Product Introduction
- 7.19.4 Merck KGaA Response to COVID-19 and Related Developments
- 7.20 Ipsen
- 7.20.1 Ipsen Business Overview
- 7.20.2 Ipsen Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.20.3 Ipsen Anti - Neoplastic Agents Product Introduction
- 7.20.4 Ipsen Response to COVID-19 and Related Developments
- 7.21 AbbVie
- 7.21.1 AbbVie Business Overview
- 7.21.2 AbbVie Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.21.3 AbbVie Anti - Neoplastic Agents Product Introduction
- 7.21.4 AbbVie Response to COVID-19 and Related Developments
- 7.22 Gilead Sciences
- 7.22.1 Gilead Sciences Business Overview
- 7.22.2 Gilead Sciences Anti - Neoplastic Agents Quarterly Production and Revenue, 2020
- 7.22.3 Gilead Sciences Anti - Neoplastic Agents Product Introduction
- 7.22.4 Gilead Sciences Response to COVID-19 and Related Developments
8 Supply Chain and Sales Channels Analysis
- 8.1 Anti - Neoplastic Agents Supply Chain Analysis
- 8.1.1 Anti - Neoplastic Agents Supply Chain Analysis
- 8.1.2 Covid-19 Impact on Anti - Neoplastic Agents Supply Chain
- 8.2 Distribution Channels Analysis
- 8.2.1 Anti - Neoplastic Agents Distribution Channels
- 8.2.2 Covid-19 Impact on Anti - Neoplastic Agents Distribution Channels
- 8.2.3 Anti - Neoplastic Agents Distributors
- 8.3 Anti - Neoplastic Agents Customers
9 Key Findings
10 Appendix
- 10.1 About Us
This report covers market size and forecasts of Anti - Neoplastic Agents, including the following market information:
Global Anti - Neoplastic Agents Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Anti - Neoplastic Agents Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Anti - Neoplastic Agents Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Anti - Neoplastic Agents Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)
Key market players
Major competitors identified in this market include Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda, Eli Lilly, AstraZeneca, Astellas, Merck & Co., Sanofi, Bayer, Biogen Idec, Eisai, Teva, Otsuka, Merck KGaA, Ipsen, AbbVie, Gilead Sciences, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy (Biologic Therapy)
Others
Based on the Application:
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Other Cancers